Champions Oncology, Inc.
CSBR
$6.80
-$0.02-0.29%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.11% | 13.54% | 19.03% | 7.19% | -1.96% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.11% | 13.54% | 19.03% | 7.19% | -1.96% |
| Cost of Revenue | 1.81% | -3.45% | -3.80% | 0.89% | -4.56% |
| Gross Profit | 20.56% | 37.59% | 53.15% | 16.15% | 1.53% |
| SG&A Expenses | -3.37% | -6.87% | -8.79% | -5.63% | -0.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.51% | -8.72% | -10.61% | -8.07% | -7.93% |
| Operating Income | 199.05% | 170.03% | 176.43% | 95.94% | 54.76% |
| Income Before Tax | 182.71% | 163.32% | 166.28% | 93.35% | 54.22% |
| Income Tax Expenses | -113.16% | -138.71% | -137.14% | -150.00% | -148.10% |
| Earnings from Continuing Operations | 186.02% | 164.61% | 166.07% | 93.79% | 55.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 186.90% | 164.61% | 166.07% | 93.79% | 55.20% |
| EBIT | 199.05% | 170.03% | 176.43% | 95.94% | 54.76% |
| EBITDA | 490.33% | 228.36% | 221.01% | 120.76% | 76.77% |
| EPS Basic | 186.37% | 164.17% | 165.46% | 93.84% | 55.20% |
| Normalized Basic EPS | 205.92% | 171.07% | 176.55% | 97.72% | 55.15% |
| EPS Diluted | 173.95% | 158.23% | 160.46% | 91.59% | 53.34% |
| Normalized Diluted EPS | 197.01% | 167.16% | 173.51% | 97.01% | 54.53% |
| Average Basic Shares Outstanding | 1.03% | 0.83% | 0.60% | 0.47% | 0.24% |
| Average Diluted Shares Outstanding | 2.19% | 3.67% | 3.44% | 2.08% | 1.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |